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Summary Twenty four patients with angio-immunoblastic lymphadenopathy (AILD) presenting between
1974 and 1985 have been reviewed. Clinical features at presentation included rash, fever, lymphadenopathy
and hepatosplenomegaly in 75% of patients. Polyclonal hypergammaglobulinaemia was seen in 19/20 patients;
5 had normal immunoglobulin levels. Combination chemotherapy with MVPP was the optimal treatment with
6/7 patients achieving complete remission. Duration of remission ranged from 9 months to 4 years and was
significantly longer in patients achieving complete as opposed to partial remission.
In 6 patients phenotype studies were performed on single cell suspensions and immunoperoxidase studies
on frozen sections of 7 lymph nodes. There was a reversal of the normal T suppressor/helper cell ratio with a
predominance of T suppressor cells. Loss of normal B follicles was observed histologically in all except one
lymph node. Germline configuration of the ,BB-chain of the T cell receptor was observed in lymph nodes of 4
patients with AILD, and a rearranged T cell receptor was observed in 1 patient in whom a second lymph
node biopsy had shown alteration of the histological picture to that of T-zone lymphoma.
Frozen sera of 15 patients were screened for antibodies to HTLV I and III and were found to be negative.
Angio-immunoblastic lymphadenopathy with dysproteinaemia
(AILD) is a clinicopathological syndrome originally des-
cribed in 1974 (Frizzera et al., 1974; Lukes & Tindle, 1975).
The pathogenesis of this condition is still not understood
clearly, although knowledge of the clinical features, natural
history and management of the disease have improved
considerably. The disease was initially believed to be a
'hyperimmune phenomenon' which was in some instances,
triggered by exposure to drugs to which the patient had
become sensitised (Lukes & Tindle, 1975; Cullen et al., 1979).
In most cases however the nature of the supposed allergen
was obscure. It was only recognised that a proportion of
cases progressed to malignant lymphoma usually of high
grade, immunoblastic type (Lukes & Tindle, 1975; Nathwani
et al., 1978). Although many clinicians at that time felt
that the clinical behaviour of the lesion was from the onset
more in keeping with a malignant neoplasm, pathologists in
general were reluctant to accept that the process was neo-
plastic in the early stages. It was widely believed that AILD
was pre-malignant, and not malignant. At the end of the
decade, Shimoyama et al., 1979 and Watanabe et al., 1980,
described a form of peripheral T-cell lymphoma which was
clinically and pathologically indistinguishable from AILD,
as it has been described in the American and European
literature. Since that time, the theory that AILD is, at least
in the majority of cases, a special type of T-cell lymphoma,
has steadily gained ground, although many of the curious
features of this disease remain unexplained.
This report presents the cumulative experience of patients
studied prospectively since the first report from St.
Bartholomew's Hospital (Cullen et al., 1979), with analysis
of lymphocyte subpopulations in 6 patients by immunohisto-
logical techniques using monoclonal antibodies. The clonality
of T cells has also been evaluated by analysis of T cell
receptor gene rearrangements in 4 patients in whom tissue
was available.
Materials and methods
Patients
Twenty-six patients with AILD, of whom 10 formed the
Correspondence: T.A. Lister.
Received 1 July 1986: and in revised form, 15 December 1986.
basis of the previous report (Cullen et al., 1979) were
referred to St. Bartholomew's Hospital between March 1974
and April 1985. All patients in whom the diagnosis of AILD
was made between 1974-1985 were reviewed histologically.
One patient was excluded as the diagnosis was changed to
reactive lymphadenitis on review of the biopsied section.
Follow up data were not available in another. The diagnosis
was confirmed in all patients by lymph node biopsy. Serial
lymph node biopsies were undertaken if there was
progression of disease on treatment, or at relapse. Routine
assessment included biochemical screening, computed
tomographic (CT) scans of abdomen and chest, and bone
marrow aspirate and biopsy. After the extent of disease had
been defined, chemotherapy was commenced and disease
status reassessed on completion of treatment.
Immunopathological studies
Lymphocytes were isolated from peripheral blood by
centrifugation on Ficoll-Triosil gradients and single cell
suspensions were prepared from excised lymph nodes or
spleen. For the immunohistological studies, sections (5pm)
were cut from frozen blocks of tissue stored in the gas phase
of liquid nitrogen, and immunostained by the avidin-biotin
conjugate method (ABC technique) and immunoperoxidase
technique as described by Dorreen et al., (1982, 1984).
Phenotypic analysis of single cell suspensions obtained in
this way was performed by the indirect immunofluorescent
assay using primary monoclonal antisera and fluoresceinated
F(ab) goat anti-mouse IgG as secondary antibody. Surface
membrane immunoglobulin expression was determined using
heterologous class specific antisera in the direct immuno-
fluorescence technique (Dorreen et al., 1984).
Molecular studies
DNA was prepared from frozen lymph nodes, digested with
restriction enzymes (ECORI, BAMH1, HINDIII and
ECORV) and transferred to nitrocellulose by the technique
of Southern (1975). The samples were hybridised using the
T-cell receptor probe CBI (Yoshikai et al., 1984) and the
immunoglobin gene JH probe as described previously (Ford
et al., 1983).
HTLV I and HTLV III serology
Sera from 15 patients stored at -70°C were screened for
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antibodies against retroviruses HTLV I and HTLV III by
the Elisa technique (Sarangadharan et al., 1984).
Results
Clinicalfeatures
The age of patients ranged between 42 and 77 years (median
53 years) except one patient who was 10 years of age.
All patients (14 men and 10 women) presented with
lymphadenopathy and other features as shown in Table I. In
one patient the disease appeared to have been precipitated
by a drug (Maloprim) and the symptoms subsided on
withdrawal of the drug and did not recur. Six other patients
developed drug related rashes during the initial presentation.
In addition to the typical features of AILD, ascites was
noted in 4 patients and pedal oedema in eight. Dyspnoea
associated with radiologically small pleural effusions was
observed in 5 patients and lung function tests in two of them
showed a restrictive type of defect. Four patients had
transient polyarthritis without radiological changes, and
bilateral carpal tunnel syndrome was observed in one
patient. Enlarged lymph nodes caused dysphagia in one
patient.
Table I Clinical features
(Totalpatients=24)
Clinicalfeatures No. ofpatients
Fever 18
Lymphadenopathy
a) generalised 15
b) localised 7
Hepatomegaly 18
Splenomegaly 16
Arthritis 5
Ascites 4
Oedema 8
Dermatological features
a) non-specific rash 18
b) purpura 3
c) nodules 2
Haematologicalprofile (Table II)
Anaemia was noted in 17/24 patients, 9 of whom had a
positive Coombs test, 5 with reticulocytosis. Leucocytosis
(>11 x 109 1-1) was present in 12/24 and eosinophilia was
prominent in 9/24 while 15 patients had lymphopenia
(<1.5 x 1091-1). Circulating atypical mononuclear cells were
observed in 9 patients. These abnormal features returned to
normal during remission in all patients.
Bone marrow examination was normal at presentation in
7/17 patients. The other ten patients had marrow
involvement characterised by a polymorphous infiltrate of
plasma cells, immunoblasts, lymphoplasmacytoid cells and
eosinophils. Trephine biopsies revealed an increase in
reticulin and vessels.
Table II Haematological features
Anaemia (< IOg1-1) 17/24
Leucocytosis (> I1 x 109 1-1) 12/24
Eosinophilia (>0.44 x 109 1 -) 9/24
Atypical cells in peripheral blood 11/24
Thrombocytopenia (< 150 x 109-l-1) 7/24
Coombs test positivity 9/24
Lymphocytopenia (< 1.5 x 109 1-') 15/24
ESR (Westergren > 150mmh-1) 9/20
Biochemicalfeatures (Table III)
Hyponatremia (<135mmoll-1) at presentation was noted
in 12/23 patients. It reverted to normal during remission.
Although hepatomegaly was observed in 18 patients, the
liver function tests were normal in all except 3 who had
hypoalbuminaemia. Enzyme studies showed hydroxy-
butyrate dehydrogenase (a nonspecific test measuring lactate
dehydrogenase enzyme levels) to be elevated in 16/17. Five
patients had biochemical evidence of hypothyroidism but
were clinically euthyroid. Two of these had antithyroid
autoantibodies. Protein electrophoresis showed hypergamma-
globulinaemia in 14 patients, a normal pattern in 5 and
hypogammaglobulinaemia in one.
Table III Biochemical features
Hypoalbuminaemia (<34g1-1) 3/24
Hyponatraemia (< 135mmol1-) 12/23
Elevated HBD (normal 40-125IU) 16/17
Abnormal thyroid function tests
indicating hypothyroidism 5/16
Hypergammaglobulinaemia 14/20
Normal immunoglobulin
electrophoresis 5/20
Hypogammaglobulinaemia 1/20
Immunopathologicalfeatures
Fresh lymph nodes were available only in 6/24 patients.
Studies on single cell suspensions in 7 lymph node biopsies
from 6 patients at presentation showed predominance of T
cells in all except one (Table IV). The majority of T cells
were of the 'suppressor' phenotype (OKT8+ve), resulting in
either a marked reduction, or reversal of the helper to
suppressor T cell ratio (Th:T3-normal range 3-4:1).
Polyclonal B cells (SIg+ve) were present in all 4 nodes
tested. The proportion of B cells was variable and correlated
with HLA-DR positive cells.
The ratio of Th:T8 in the peripheral blood was reversed in
2 out of 3 patients in whom the disease had altered to a T-
zone lymphoma at the time of testing, whilst the Th:TS ratio
was within normal limits in the third patient with AILD
(untransformed).
Immunoperoxidase studies (Table V)
Immunoperoxidase studies on frozen sections of the same
nodes showed the overall preponderance of T cells and
confirmed the reversal of Th:T5 ratio observed in single cell
suspension studies of 2 patients. In 3 other patients only a
reduction of Th:TS ratio was noted (1.5 to 2.0). The T cells
were distributed as a diffuse infiltrate over the entire lymph
node. Natural killer cells (detected by reaction with the Leu
7 antibody) were increased (10-30%) in 2/5 nodes compared
with normal or reactive nodes and did not show the usual
localisation in follicles or follicle-like structures. In 1 patient
(GR) increased proportions of Leu 7+ve cells were still
evident in blood and lymph node tissue at the time of
transformation into T-zone lymphoma. The absence of
residual B cell follicles and a diffuse T cell infiltrate were
prominent features in all but one case of AILD. Reaction
with OKT9 (transferrin receptor antibody) was not increased
in three lymph nodes tested and in one patient the germinal
centre cells were positive. Only the large blast like T cells
were OKT9 positive in one lymph node with features of T-
zone lymphoma.
Serologyfor HTLV I and III
Screening on frozen sera of 15 patients for antibodies against
HTLV I and III was performed and was found to be
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Table IV Phenotypic studies of single cell suspensions. (All figures are expressed as percentages oftotal viable mononuclear cells)
E. Rosettes Th Ts
Patient +ve cells Pan T* (OKT4/Leu 3a) (OKT8-Leu 2a) Th:Ts OKTh (smIg) Ia
A: Lymph Node
1 JP 18 27 22.5 11.5 2:1 6 27 (polyclonal) 21
2 DD 67 57 38 NT or <1 - 40
3 GR 61 94 29 64 1:2 - 4
4 WP 57 >95 36 73 1:2 6 1-2 (polyclonal) 27
5 IM (1980) 50 70 15 27 1:2 - 29 (polyclonal)
(1981) 14 30 2 9 1:4.5 46 (polyclonal)
6 EP - 60 34 27 1.3:1 - 10 (polyclonal)
B. Blood
1 DD 45 70 51 4.7:1 - 30
2 GR 79 12 64 1:5 0 BI-2 1
3 WP 50 89 26 62 1:2.4 10
*Reactivity with OKT1 or OKT3.
Controls:
Mean+ 39
s.e. 6
55
6
47
3
4:1 <5 16
3
23
2
Table V Immunoperoxidase studies of the distribution oflymphocyte subpopulations in involved lymph nodes
T4/Leu 3a T8/Leu
Patient T cell reaction (%) (%) Th: Ts Leu-7 OKT9 OKM/i Mo-2
IM ++/+++ 70 30 2:1 <10%: focal neg <1%
distribution
DD +++ 15 86 1:6 <1% neg 15-25%
GR + + +/+ + + + 30 70 1:2 30%: even some +ve
distribution larger cells
RP + + + 60 40 1.5:1 10-30% neg
marked interfollicular
reaction. Also germinal
ctrs & mantle zones
PB + + + 60 40 1.5:1 <1% diffuse stain 20-30%
ofmo's
GR (NHL) + + + + 60 40 1.5:1 10-30%: germ ctr. 10-15%
as for RP cells, mo's &
lymphoma cells
+ + =moderate + + + =marked + + + + =intense
Note: All percentages quoted are approximate estimates.
Molecular analysis of immunoglobulin and T cell receptor
genes
Analysis of fB chain of the T cell receptor (CBl) and
immunoglobulin genes for rearrangement showed no
evidence of a clonal population of T or B cells in lymph
nodes of 4 patients with AILD in whom frozen lymph node
tissue was available. However in one patient whose disease
had evolved to a T-zone lymphoma, there was clonal
rearrangement of the flB chain of the T cell receptor gene.
Clinical course (Table VI)
Five patients received no therapy initially and 2 of these had
prolonged freedom from disease after a spontaneous
remission, for 4 and 6 years respectively. Prednisolone was
used alone in 3 patients with 1 patient achieving a complete
remission lasting 2 years. Cyclophosphamide and prednisolone
were given to 8 patients as initial therapy. Only 1 patient had
a complete remission, with 4 partial responses; the rest failed
to respond. Six out of seven patients receiving combination
chemotherapy comprising mustine, vinblastine, prednisolone
and procarbazine (MVPP) (Sutcliffe et al., 1978) achieved
complete remission. The duration of remission ranged from
9 months to 37 months (median 4 months). Five patients
developed overt non Hodgkin's lymphoma (T-zone lym-
phoma in 2 patients and immunoblastic lymphoma in 3
patients) (Table VII). This was evident on lymph node
biopsy during relapse or progression of disease. The trans-
Table VI Overall response to treatment
Duration ofremission
No. ofpts. (months)
Initial treatment No. ofpts. CR PR/fail Range Median
MVPP 7 6 1 9-37 24
Cyclophosphamide and
prednisolone 8 1 7 9 9
Prednisolone 3 1 2 26 26
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Table VII Details of patients transforming to a high grade lymphoma
Response to Duration of Histology of
therapyfor remission transformed Response to therapy Survival after diagnosis
Pt. No. AILD (months) lymphoma after transformation oftransformation
I CR 24 T zone not assessable 8
lymphoma
2 Fail 4 T zone not assessable 11
lymphoma
3 CR 71 IL CR 15
4 Fail 6 IL NR 6
5 PR 21 IL CR 7
formation was not associated with any change in clinical
behaviour. Although complete remission of the lymphoma
was achieved with combination therapy in 2 patients, it was
followed by early relapse and all these patients died within
a year.
The overall survival for all the patients is as shown in
Figure 1. Survival was longer in patients achieving complete
remission (P<0.03) (Figure 2).
Autopsy details are available in 7 patients (Table VIII).
The cause of death appeared to be related to immuno-
suppression in 3 patients. Two patients had cytomegalovirus
in the lungs, and one had pneumocystis pneumonia.
Immunoblastic lymphoma was diagnosed at post mortem in
one patient.
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Figure 1 Overall survival of AILD patients.
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Figure 2 Overall survival of AILD patients according to
response to therapy.
Discussion
The clinical features of AILD at presentation in this series
are similar to those reported in the literature (Frizzera et al.,
1974; Lukes & Tindle, 1975; Schauer et al., 1981; Pruzanski,
1980), namely rapid onset of constitutional symptoms with
rash, generalised lymphadenopathy, and hepatospleno-
N - 24 megaly. Dermatological manifestations in three-quarters
of the patients consisted of a non-specific papular rash.
8 Three patients presented with purpura, and 2 had nodular
skin lesions, as described by Bernengo et al., (1981),
with histological features of AILD on skin biopsy.
Haemolytic anaemia (HA) was a presenting feature in a
Table VIII Summary of post mortem findings
Pt. No. AILD LYMPHOMA PNEUMONIA UNRELATED
1 + Haematemesis
splenic rupture
2 + Peritonitis
in lymph nodes
3 - + Myocardial
infarction
4 + - +
5 Fibrosis with Cytomegalovirus Myocardial
lymphocyte pneumocystis infarction
depletion in
lymph nodes
Pulmonary infarct
6 Lymphoma Diverticulitis
silent perforation
of pelvic colon
7 Hyalin tissue Cytomegalovirus Ulcer first part of
in lymph nodes duodenum
1
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quarter of the patients with a positive Coombs reaction,
exhibiting IgG and C3d on the red cells. A lower incidence
of HA has been reported by others (Neiman et al., 1978;
Pangalis et al., 1978).
Although hypergammaglobulinaemia was an integral part
of the AILD syndrome as first described, (Frizzera et al.,
1974; Lukes & Tindle, 1975), five out of 24 patients in this
series had normal immunoglobulin levels at presentation,
which later became elevated, and one patient presented with
hypogammaglobulinaemia. Hypothyroidism with autoanti-
bodies is not a common feature in previous reports
(Watanabe et al., 1977). In this study, 5 out of 24 patients
had laboratory evidence of thyroid dysfunction whilst
clinically euthyroid.
The histopathological features of AILD in a lymph node
biopsy are distinctive despite the uncertainty which
surrounds their interpretation. The normal architecture of
the node is effaced, with disappearance of follicles and gross
reduction of typical small lymphocytes which are replaced by
a polymorphic infiltrate of immunoblasts, plasma cells
eosinophils, histiocytes and atypical lymphocytes with
irregularly shaped nuclei which mark as T cells on
immunostaining. Mitoses are sometimes numerous. A
prominent feature is the arborising vascular proliferation
which accompanies the infiltration and in some instances the
deposition of amorphous eosinophilic material. (Lukes &
Tindle, 1975; Frizzera et al., 1974).
Clinically and pathologically AILD has many features
suggestive of an abnormal immune reaction. There is
evidence of an abnormal sensitivity to drugs in some
patients, the frequent occurrence of skin rashes, and less
frequently arthropathy; also a tendency to spontaneous
remissions, especially in the early stages of the disease.
Pathologically the observation of polyclonal hypergamma-
globulinaemia in most cases, the frequent occurrence of
autoimmune phenomenona (Coombs-positive haemolytic
anaemia, thrombocytopenia) and alteration or reversal of the
Th/TS ratio, all indicate an immune disturbance. Delayed
hypersensitivity tests may show cutaneous anergy to
common antigens implying dysfunction of T-helper/inducer
function. Frizzera et al. (1974) likened the process to a graft
versus host reaction, whilst Lukes and Tindle (1975) raised
the possibility that certain drugs might give rise to a
prolonged and disordered hypersensitivity reaction. Because
of the often marked plasma cell infiltration, immunoblastic
proliferation and the almost invariable polyclonal hyper-
gammaglobulinaemia, a primary disorder of the B cell
lineage was earlier suspected, (Lukes & Tindle, 1975). The
frequent transformation of AILD to immunoblastic
lymphoma (Nathwani et al., 1978; Newcom et al., 1979b;
Cullen et al., 1979) has also been cited as supportive
evidence of a B cell disorder.
The more recent observations of T cell subsets alteration
has directed attention away from B cells to that of T cells. In
this study, a reversal of ThITS ratio and an absolute increase
in T cells was observed in cell suspensions of lymph nodes
from 6 patients and similar findings have been reported in
the peripheral blood lymphocytes in two young males with
AILD (Stensvold et al., 1984). In this regard, the similarity
to the findings to HIV infection are noteworthy, and
prompted investigation ofwhether HTLV I or HTLV III play
an aetiological role in AILD (Poeisz et al., 1980; Takatsuki
et al., 1977). Recently there was a report describing an
association of AILD and acquired immunodeficiency
syndrome (AIDS) in two patients (Blumenfield et al., 1983).
Frozen sera from 15 patients in the present series were tested
and found to be negative for antibodies to these viruses.
That AILD may transform into a high grade lymphoma
is well known, but the phenotype has been established only
in a few cases. Lennert (1981) recorded the transformation
of a case of AILD into a T-zone lymphoma and the
same sequence was observed in 2 cases of the present series.
One termination of AILD as a T-cell lymphoma of
T8(suppressor) phenotype has been recorded (Rubenstein &
Dauber, 1983). Only in the last few years has the proposition
been advanced that many cases of AILD may in fact be T-
cell lymphomas from the outset. This was first suggested by
a group of Japanese workers (Shimoyama et al., 1979;
Watanabe et al., 1980) who desribed a series of immuno-
blastic lymphadenopathy-like T-cell lymphomas with clinical
and pathological features similar to AILD, including the
occurrence of polyclonal hypergammaglobulinaemia. In
addition to the behaviour of the disease in their patients,
these authors adduced the finding of karyotypic
abnormalities as evidence for the neoplastic nature of the
disease.
The idea that AILD might, in many instances at least, be
a special type of peripheral T-cell lymphoma, has led in the
past few years to a reappraisal of the clinical and
pathological features of this condition. With increased
recognition of the special peculiarities of peripheral T-cell
lymphomas the idea no longer seems improbable, as it did
10 years ago. Indeed several of the histological features of
AILD are shared by other recognised varieties of peripheral
T-cell lymphoma. In view of the acknowledged tendency in
T-cell lymphomas for the histological picture to change
between one biopsy and the next (Stansfeld, 1985) it is not
surprising that the picture of AILD should sometimes
change into that of a T-zone lymphoma.
Further support for the neoplastic nature of AILD has
come from 2 sources. First, karyotypic abnormalities have
been shown in lymph nodes from patients with AILD.
Secondly, clonal rearrangement of the # chain on the T cell
receptor gene has been shown in such lymph nodes. Whilst
clonal rearrangement does not constitute final proof of the
neoplastic nature of the disease it is certainly suggestive of
neoplasia. The results are not, however, entirely consistent.
In a series of 24 patients with AILD, O'Connor and Mason
(1986), showed clonal rearrangements of the # chain of the
T cell receptors only in 2/3. Similar results were reported by
Bertness et al. (1985), Downing et al., (1985) and Weiss et al.
(1986). Further, it was shown in the above reports that 2
patients showed T cell clonality only when the disease
evolved into a definite T-cell lymphoma. In the present
study, none of the four patients showed evidence of T cell
clonality in the first biopsy. In conformity with the reports
cited above, however, rearrangement was found in one
patient after his disease had evolved into a T-zone
lymphoma.
Whilst it is still possible that AILD showing the germline
pattern of the T cell receptor gene is neoplastic (the clonal
population may be too small for detection), it is also possible
that AILD in its initial stages is preneoplastic, as suggested
earlier. Such a theory prompts the question as to whether it
is possible to distinguish histologically between premalignant
and malignant stages of the disease, which seems almost
invariably to declare itself as become malignant in course of
time. In a recent study, cited above, (Weiss et al., 1986), the
authors attempted to distinguish morphologically between
AILD and AILD-like lymphoma in a series of 10 patients. T
cell clonality was found in three out of five specimens from
patients whose biopsies were interpreted as showing AILD
and in five out of six specimens where the diagnosis was
AILD-like lymphoma. It thus seems fairly clear that
'premalignant' and malignant phases of AILD cannot be
reliably distinguished morphologically. A recent study (Clark
et al., 1986) holds out hope that a simpler method of
assessing T cell clonality may be available in the near future.
Few would doubt that the established disease is, in the great
majority of cases, a T-cell lymphoma.
Only one patient in the present series (Case 11 of the
previous report - Cullen et al., 1979) seems to be different in
that his disease was clearly due to sensitisation to a drug -
Maloprim (Dapsone and Pyrimethamine), taken for malarial
prophylaxis. Lymphadenopathy and rash recurred every time
this drug was taken and resolved subsequently. He recovered442 T.S. GANESAN et al.
completely when this drug was withdrawn. The histological
features in the lymph node biopsy were indistinguishable
from those of AILD, but from the history it was a reversible
drug reaction.
Prednisolone was initially suggested as the treatment of
choice (Lukes et al., 1975; Frizzera et al., 1974; Newcom et
al., 1979a) because AILD was originally considered to be a
benign hyperimmune akin to a drug reaction (Lukes &
Tindle, 1975). It soon became apparent that this form of
therapy was ineffective in maintaining a disease-free state in
most patients. A review of the clinical behaviour of AILD in
many published cases suggests that achievement of complete
remission prolongs survival (Pangalis et al., 1983). Intensive
cytotoxic therapy seems to achieve remission in a higher
proportion of cases if given as the first line of treatment.
This is certainly reflected in this study, where 6 out of 7
patients achieved complete remission when treated with
MVPP. Progression to a high grade lymphoma is uniformly
associated with a fatal outcome (Nathwani et al., 1978;
Pangalis et al., 1983). Two patients achieved a complete
remission of supervening high grade lymphoma with 6 cycles
of MVPP. Despite this, all patients whose disease
transformed died within 15 months. The overall survival was
however disappointing with only four of the 24 patients
being alive at the time of reporting. This is in accordance
with other reports (Pangalis et al., 1983).
The necessity for intensive cytotoxic treatment has been
questioned (Frizzera et al., 1975). Treatment produces
complete resolution of symptoms and signs. Furthermore, as
shown previously and confirmed in this study, treatment
improves the quality of life and reverses abnormal clinical
and laboratory parameters. In spite of this cytotoxic
treatment is clearly not curative and maybe inappropriate for
elderly patients.
In conclusion AILD and AILD-like peripheral T-cell
lymphoma are similar clinically and pathologically
indistinguishable. However, available evidence still does not
conclusively prove the neoplastic nature of AILD.
Management is difficult but intensive therapy does produce a
durable complete remission.
Serological investigations for HTLV I and HTLV III and T cell
receptor gene rearrangement studies were conducted in Professor M.
Greaves' laboratory (Leukaemia Research Fund Centre, Institute of
Cancer Research). Miss K. Ash collated the data and Jane Ashby
typed the manuscript.
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